Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHANE M DRAHOS

Allopathic & Osteopathic Physicians Family Medicine Sleep Medicine

NPI
1952780934
CMS profile
2880500
Location
WINTER GARDEN, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$91,128.22

208 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
JAZZ PHARMACEUTICALS INC. $90,843.22 207
Vertex Pharmaceuticals Incorporated $285.00 1

Page 2 of 5; records 51–100 of 208 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHANE M DRAHOS

NPI 1952780934 · CMS profile ID 2880500

Allopathic & Osteopathic Physicians / Family Medicine / Sleep Medicine

WINTER GARDEN, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 208 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1952780934?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHANE M DRAHOS, NPI 1952780934, CMS profile ID 2880500. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 208 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1952780934?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SHANE M DRAHOS, NPI 1952780934, CMS profile ID 2880500. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 208 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1952780934?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SHANE M DRAHOS, NPI 1952780934, CMS profile ID 2880500, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 208 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1952780934?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

208 matching records · $91,128.22 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 208 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 208.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Jazz Pharmaceuticals Inc. $3,060.0005/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086279 CMS
Jazz Pharmaceuticals Inc. $49.5005/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086321 CMS
Jazz Pharmaceuticals Inc. $1,530.0005/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086343 CMS
Jazz Pharmaceuticals Inc. $11.8505/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086371 CMS
Jazz Pharmaceuticals Inc. $546.2805/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086391 CMS
Jazz Pharmaceuticals Inc. $2,040.0005/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086399 CMS
Jazz Pharmaceuticals Inc. $350.0005/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086403 CMS
Jazz Pharmaceuticals Inc. $1,443.5605/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086143 CMS
Jazz Pharmaceuticals Inc. $140.0005/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086149 CMS
Jazz Pharmaceuticals Inc. $22.2605/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086157 CMS
Jazz Pharmaceuticals Inc. $22.0005/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086159 CMS
Jazz Pharmaceuticals Inc. $298.3205/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086161 CMS
Jazz Pharmaceuticals Inc. $408.3905/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086173 CMS
Jazz Pharmaceuticals Inc. $100.0005/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086179 CMS
Jazz Pharmaceuticals Inc. $2,040.0005/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086341 CMS
Jazz Pharmaceuticals Inc. $5,100.0005/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086393 CMS
Jazz Pharmaceuticals Inc. $4,080.0005/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086353 CMS
Jazz Pharmaceuticals Inc. $2,040.0005/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086367 CMS
Jazz Pharmaceuticals Inc. $225.7205/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086283 CMS
Jazz Pharmaceuticals Inc. $225.7205/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086287 CMS
Jazz Pharmaceuticals Inc. $225.7205/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086289 CMS
Jazz Pharmaceuticals Inc. $225.7205/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086291 CMS
Jazz Pharmaceuticals Inc. $125.1405/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086395 CMS
Jazz Pharmaceuticals Inc. $144.9505/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086397 CMS
Jazz Pharmaceuticals Inc. $30.2505/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086319 CMS
Jazz Pharmaceuticals Inc. $215.3505/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086239 CMS
Jazz Pharmaceuticals Inc. $215.3405/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086331 CMS
Jazz Pharmaceuticals Inc. $215.3505/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086339 CMS
Jazz Pharmaceuticals Inc. $24.0705/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086373 CMS
Jazz Pharmaceuticals Inc. $4,590.0005/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086355 CMS
Jazz Pharmaceuticals Inc. $642.6005/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086311 CMS
Jazz Pharmaceuticals Inc. $765.0005/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086225 CMS
Jazz Pharmaceuticals Inc. $125.0004/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086375 CMS
Jazz Pharmaceuticals Inc. $119.4504/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086231 CMS
Jazz Pharmaceuticals Inc. $119.4504/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086233 CMS
Jazz Pharmaceuticals Inc. $119.4504/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086235 CMS
Jazz Pharmaceuticals Inc. $123.6604/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086237 CMS
Jazz Pharmaceuticals Inc. $43.5004/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086245 CMS
Jazz Pharmaceuticals Inc. $167.9004/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086247 CMS
Jazz Pharmaceuticals Inc. $43.5004/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086249 CMS
Jazz Pharmaceuticals Inc. $43.5004/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086251 CMS
Jazz Pharmaceuticals Inc. $43.5004/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086253 CMS
Jazz Pharmaceuticals Inc. $43.5004/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086255 CMS
Jazz Pharmaceuticals Inc. $43.5004/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086257 CMS
Jazz Pharmaceuticals Inc. $128.9204/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086261 CMS
Jazz Pharmaceuticals Inc. $43.5004/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086293 CMS
Jazz Pharmaceuticals Inc. $43.5004/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086295 CMS
Jazz Pharmaceuticals Inc. $43.5004/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086297 CMS
Jazz Pharmaceuticals Inc. $43.5004/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086299 CMS
Jazz Pharmaceuticals Inc. $43.5004/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086301 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $125.17 2
PY2020 $117.95 3
PY2021 $184.80 7
PY2022 $47,483.58 69
PY2023 $91,128.22 208
PY2024 $97,154.93 99
PY2025 $80,810.61 106

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $117,602.15 73

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

73 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,903.18 11/13/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074346
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $66.00 08/30/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074392
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $300.00 08/27/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074332
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9,250.80 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074312
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9,609.60 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074314
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,644.60 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074316
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,718.60 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074318
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,718.60 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074320
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,718.60 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074322
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074324
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9,609.60 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074326
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9,250.80 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074328
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,718.60 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074330
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074336
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074338
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9,609.60 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074342
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,718.60 08/07/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074344
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $400.00 07/10/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074334
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $835.90 07/03/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074308
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $708.50 07/03/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074310
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $824.98 07/03/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074340
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.66 07/02/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074388
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.92 07/02/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074390
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $90.00 06/14/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074296
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,100.00 06/14/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074306
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $65.91 06/03/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074304
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,692.52 05/17/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074278
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $180.00 05/17/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074298
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 05/17/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074300
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,438.50 05/03/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074280
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,258.40 05/03/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074282
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $708.50 05/03/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074284
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 05/03/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074286
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,002.30 05/03/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074288
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $835.90 05/03/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074290
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $22.00 05/02/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074384
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.41 05/02/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074386
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 04/12/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074292
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $150.00 04/12/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074294
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,002.30 04/01/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074302
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $46.75 03/29/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074372
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.71 03/29/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074374
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $389.09 03/18/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074266
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $902.07 03/18/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074268
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 03/18/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074270
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,212.90 03/18/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074276
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,550.00 03/13/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074248
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $50.70 03/13/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074250
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $150.00 03/13/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074252
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $180.00 03/13/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074254
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $300.00 02/14/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074256
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7,059.70 02/14/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074258
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,094.65 02/14/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074260
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,479.00 02/14/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074262
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $150.00 02/14/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074264
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 02/14/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074272
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $993.00 02/14/2024 Non-covered Recipient Entity
BioSerenity Inc.
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074274
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $66.00 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074348
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4.80 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074350
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.90 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074352
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3.96 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074354
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $90.84 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074356
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $46.87 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074358
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $11.52 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074360
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $50.84 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074362
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $20.88 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074364
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $28.05 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074366
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $221.38 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074368
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.71 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074370
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $91.22 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074376
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $356.10 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074378
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $306.72 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074380
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.41 01/03/2024 Non-covered Recipient Entity
BioSerenity Research
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1150074382